Bladder Management in Patients With Multiple Sclerosis: Optimizing Pra
Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
What it found
Results are posted in the registry, but without a statistical test of the main measure. See the numbers below.
What was tested
Treatment tested
- Systematic Screening and Education Regimen
Results by group
Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores
Baseline, Month 6
| Group | Value | Interval | Number analysed |
|---|---|---|---|
| All Enrolled Patients | 39.7 Scores on a Scale | 23.1 (Standard Deviation) | 112 |
| All Enrolled Patients | 2.5 Scores on a Scale | 22.3 (Standard Deviation) | 112 |
| All Enrolled Patients | 60.7 Scores on a Scale | 23.8 (Standard Deviation) | 112 |
| All Enrolled Patients | 1.2 Scores on a Scale | 24.2 (Standard Deviation) | 112 |
| All Enrolled Patients | 43.8 Scores on a Scale | 29.6 (Standard Deviation) | 112 |
| All Enrolled Patients | -6.9 Scores on a Scale | 27.5 (Standard Deviation) | 112 |
| All Enrolled Patients | 45.3 Scores on a Scale | 28 (Standard Deviation) | 112 |
| All Enrolled Patients | -9.8 Scores on a Scale | 26.3 (Standard Deviation) | 112 |
| All Enrolled Patients | 31.7 Scores on a Scale | 28.6 (Standard Deviation) | 112 |
| All Enrolled Patients | -9.0 Scores on a Scale | 24.5 (Standard Deviation) | 112 |
| All Enrolled Patients | 25.9 Scores on a Scale | 30.3 (Standard Deviation) | 112 |
| All Enrolled Patients | -9.0 Scores on a Scale | 24.9 (Standard Deviation) | 112 |
| All Enrolled Patients | 35.7 Scores on a Scale | 28.4 (Standard Deviation) | 112 |
| All Enrolled Patients | -9.0 Scores on a Scale | 21.8 (Standard Deviation) | 112 |
| All Enrolled Patients | 41.7 Scores on a Scale | 27.8 (Standard Deviation) | 112 |
| All Enrolled Patients | -8.2 Scores on a Scale | 25.1 (Standard Deviation) | 112 |
| All Enrolled Patients | 46.9 Scores on a Scale | 23.7 (Standard Deviation) | 112 |
| All Enrolled Patients | -5.7 Scores on a Scale | 17.7 (Standard Deviation) | 112 |
Values as posted on ClinicalTrials.gov. Outcomes measured differently across trials are not directly comparable.
Safety
| Group | Participants at risk | Serious adverse events | Deaths |
|---|---|---|---|
| All Enrolled Patients | 0 | 0 |
As posted on ClinicalTrials.gov. Serious adverse events include any serious health event during the trial, whether or not the treatment caused it.
What it measured
Main measures
Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores
Baseline, Month 6
Bladder, bowel and sexual functionMood and sleepQuality of life (reported by participants)
Other measures (1)
Percentage of Patients Who Agree/Completely Agree With Each Question on the Patient Post-Video Questionnaire
Baseline
Bladder, bowel and sexual function
Who could take part
Relapsing MS · 18 and over
Show the full criteria
Inclusion criteria
* Diagnosis of relapsing-remitting multiple sclerosis and currently being treated by study doctor
Exclusion criteria
* Diagnosis of primary-progressive, secondary-progressive, or progressive-relapsing multiple sclerosis
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This study will assess the impact of a systematic bladder health screening and disease education regimen as well as the implementation of a referral process on the quality of life of multiple sclerosis patients with bladder dysfunction.
Loading reviews and guidelines…
History
Started
Aug 2013
Main results due
Mar 2015
Finished
Mar 2015
Results posted
May 2016